Viva Biotech Holdings Net Assets
Viva Biotech Holdings net assets. Based on the latest financial reports, Viva Biotech Holdings (VB0) has net assets worth €3.91 Billion EUR (≈ $4.57 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.88 Billion ≈ $8.05 Billion USD) and total liabilities (€2.98 Billion ≈ $3.48 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Viva Biotech Holdings equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.91 Billion |
| % of Total Assets | 56.77% |
| Annual Growth Rate | 63.02% |
| 5-Year Change | 1.58% |
| 10-Year Change | N/A |
| Growth Volatility | 192.71 |
Net Assets of Viva Biotech Holdings (2016–2024)
Net assets of Viva Biotech Holdings from 2016 to 2024. This chart illustrates how Viva Biotech Holdings's net assets have evolved over time, based on quarterly financial data. See VB0 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Viva Biotech Holdings (2016–2024)
The table below shows the annual net assets of Viva Biotech Holdings from 2016 to 2024. For live market cap and overall valuation, see VB0 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.82 Billion ≈ $4.46 Billion |
+3.48% |
| 2023-12-31 | €3.69 Billion ≈ $4.31 Billion |
+2.31% |
| 2022-12-31 | €3.60 Billion ≈ $4.21 Billion |
-7.89% |
| 2021-12-31 | €3.91 Billion ≈ $4.58 Billion |
+4.17% |
| 2020-12-31 | €3.76 Billion ≈ $4.39 Billion |
+111.37% |
| 2019-12-31 | €1.78 Billion ≈ $2.08 Billion |
+606.88% |
| 2018-12-31 | €251.44 Million ≈ $293.96 Million |
+64.60% |
| 2017-12-31 | €152.76 Million ≈ $178.59 Million |
+99.68% |
| 2016-12-31 | €76.50 Million ≈ $89.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Viva Biotech Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1764.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Viva Biotech Holdings Net Assets Breakdown (December 2024)
Viva Biotech Holdings net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €4.09 Billion | 107.53% |
| Total Equity | €3.80 Billion | 100.00% |
Viva Biotech Holdings Competitors by Market Cap
The table below lists competitors of Viva Biotech Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
$337.84 Million |
|
Aramis SAS
PA:ARAMI
|
$337.84 Million |
|
JinGuan Electric Co Ltd
SHG:688517
|
$337.84 Million |
|
Singer Thailand Public Company Limited
BK:SINGER
|
$337.90 Million |
|
Transcontinental Realty Investors
NYSE:TCI
|
$337.71 Million |
|
Teqnion AB
ST:TEQ
|
$337.69 Million |
|
Junhe Pumps Holding Co Ltd
SHG:603617
|
$337.69 Million |
|
Seoul Food
KO:004410
|
$337.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viva Biotech Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,687,912,000 to 3,802,377,000, a change of 114,465,000 (3.1%).
- Net income of 167,294,000 contributed positively to equity growth.
- Share repurchases of 23,019,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €167.29 Million | +4.4% |
| Share Repurchases | €23.02 Million | -0.61% |
| Other Changes | €-29.81 Million | -0.78% |
| Total Change | €- | 3.10% |
Book Value vs Market Value Analysis
This analysis compares Viva Biotech Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.37x to 0.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.10 | €0.14 | x |
| 2018-12-31 | €0.17 | €0.14 | x |
| 2019-12-31 | €1.14 | €0.14 | x |
| 2020-12-31 | €1.97 | €0.14 | x |
| 2021-12-31 | €2.04 | €0.14 | x |
| 2022-12-31 | €1.88 | €0.14 | x |
| 2023-12-31 | €1.72 | €0.14 | x |
| 2024-12-31 | €1.80 | €0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viva Biotech Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.42%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.85x
- Recent ROE (4.40%) is below the historical average (12.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 31.99% | 25.36% | 0.95x | 1.33x | €16.82 Million |
| 2017 | 49.92% | 51.44% | 0.73x | 1.32x | €60.98 Million |
| 2018 | 36.01% | 43.11% | 0.40x | 2.11x | €65.41 Million |
| 2019 | 14.96% | 82.30% | 0.17x | 1.07x | €88.13 Million |
| 2020 | -10.30% | -55.51% | 0.09x | 2.17x | €-762.56 Million |
| 2021 | 7.35% | 13.67% | 0.26x | 2.06x | €-103.79 Million |
| 2022 | -14.66% | -22.21% | 0.30x | 2.20x | €-888.95 Million |
| 2023 | -3.15% | -5.39% | 0.29x | 2.02x | €-484.90 Million |
| 2024 | 4.40% | 8.42% | 0.28x | 1.85x | €-212.94 Million |
Industry Comparison
This section compares Viva Biotech Holdings's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viva Biotech Holdings (VB0) | €3.91 Billion | 31.99% | 0.76x | $337.78 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more